We used multiple SCC tumor models and therapeutics to show that when TGFβ inhibition is combined with PD-L1 blockade, the effect on survival is improved over either single agent alone, with responding mice exhibiting complete tumor eradication and long-term antitumor immunity. The gene discussed is TGFB1; the disease is neoplasm.